CCCC
NasdaqC4 Therapeutics, Inc.
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$45.8M
2021
$31.1M
2022
$20.8M
2023
$35.6M
2024
$35.9M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$35.9M
Net Income$-105.0M
Gross Profit—
Oper Income$-115.2M
EPS (dil)$-1.27
Rev/sh$0.33
FCF/sh$-0.90
Book/sh$2.32
Gross M—
Oper M-320.5%
Profit M-292.1%
FCF M-276.2%
ROE-40.9%
ROA-29.2%
ROIC-64.6%
R&D/Rev290.0%
Rev Y/Y1.0%
Rev 3Y CAGR5.0%
EPS Y/Y16.4%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+19.5%
Current Ratio7.81
Quick Ratio—
Debt/Eq—
Int Coverage—
Net Debt—
Total Debt—
Cash & Eq$78.0M
Total Assets$359.1M
Oper CF$-98.7M
Capex$607,000
Free CF$-99.3M
Buybacks$193,000
Equity$256.6M
Liabilities$102.5M
Shs Outstand0.11B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $45.8M | $31.1M | $20.8M | $35.6M | $35.9M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-82.1M | $-129.5M | $-139.0M | $-119.6M | $-115.2M |
| Net Income | $-83.9M | $-128.2M | $-132.5M | $-105.3M | $-105.0M |
| Diluted EPS | $-1.82 | $-2.62 | $-2.67 | $-1.52 | $-1.27 |
| Operating Cash Flow | $-87.0M | $-105.9M | $-106.8M | $-65.2M | $-98.7M |
| Free Cash Flow | $-88.2M | $-111.4M | $-108.5M | $-65.3M | $-99.3M |
COMMUNITY · $CCCC0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.